Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372383 · ClinicalTrials.gov registry record · NA
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02372383 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 31 participants.
The verdict
NCT02372383, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
Interventions
- DRUG Azithromycin
- DRUG Ethambutol
- DRUG Rifampin
- DRUG Pancrelipase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02372383
The ClinicalTrials.gov registry entry for NCT02372383 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Azithromycin is the first listed.
NCT02372383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02372383 about?
NCT02372383 is a clinical study titled "Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis". The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
What is the current status of trial NCT02372383?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2014-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02372383?
The interventions under investigation include: Azithromycin (DRUG), Ethambutol (DRUG), Rifampin (DRUG), Pancrelipase (DRUG).
Who is sponsoring clinical trial NCT02372383?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.